Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Melvyn Lynn

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Journal of Endotoxin Research|April 17, 2003
Antagonism of in vivo and ex vivo response to endotoxin by E5564, a synthetic lipid A analogueDaniel P Rossignol, Melvyn Lynn
Current Opinion in Investigational Drugs (London, England : 2000)|May 26, 2005
TLR4 antagonists for endotoxemia and beyondDaniel P Rossignol, Melvyn Lynn
Innate Immunity|November 29, 2008
Continuous pharmacodynamic activity of eritoran tetrasodium, a TLR4 antagonist, during intermittent intravenous infusion into normal volunteersDaniel P Rossignol, Nancy Wong, Robert Noveck, et al.
Shock (Augusta, Ga.)|June 25, 2011
Influence of severity of illness on the effects of eritoran tetrasodium (E5564) and on other therapies for severe sepsisAndre C Kalil, Steven P LaRosa, Jagadish Gogate, et al.
Journal of Clinical Pharmacology|July 15, 2003
Safety, pharmacokinetics, and pharmacodynamics of E5564, a lipid A antagonist, during an ascending single-dose clinical studyY Nancy Wong, Daniel Rossignol, Jeffrey R Rose, et al.
Innate Immunity|March 9, 2011
Deactivation of the lipopolysaccharide antagonist eritoran (E5564) by high-density lipoprotein-associated apolipoproteinsJacklyn G Fleischer, Dan Rossignol, Gordon A Francis, et al.
Chest|September 15, 2004
Experimental human endotoxemia is associated with depression of load-independent contractility indices: prevention by the lipid a analogue E5531Anand Kumar, Eugene Bunnell, Melvyn Lynn, et al.
Antimicrobial Agents and Chemotherapy|August 26, 2004
Safety, pharmacokinetics, pharmacodynamics, and plasma lipoprotein distribution of eritoran (E5564) during continuous intravenous infusion into healthy volunteersDaniel P Rossignol, Kishor M Wasan, Eugene Choo, et al.
Critical Care Medicine|August 8, 2009
Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsisMark Tidswell, William Tillis, Steven P Larosa, et al.
The Journal of Infectious Diseases|February 25, 2003
Blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemiaMelvyn Lynn, Daniel P Rossignol, Janice L Wheeler, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Journal of Endotoxin Research|April 17, 2003
Antagonism of in vivo and ex vivo response to endotoxin by E5564, a synthetic lipid A analogueDaniel P Rossignol, Melvyn Lynn
Current Opinion in Investigational Drugs (London, England : 2000)|May 26, 2005
TLR4 antagonists for endotoxemia and beyondDaniel P Rossignol, Melvyn Lynn
Innate Immunity|November 29, 2008
Continuous pharmacodynamic activity of eritoran tetrasodium, a TLR4 antagonist, during intermittent intravenous infusion into normal volunteersDaniel P Rossignol, Nancy Wong, Robert Noveck, et al.
Shock (Augusta, Ga.)|June 25, 2011
Influence of severity of illness on the effects of eritoran tetrasodium (E5564) and on other therapies for severe sepsisAndre C Kalil, Steven P LaRosa, Jagadish Gogate, et al.
Journal of Clinical Pharmacology|July 15, 2003
Safety, pharmacokinetics, and pharmacodynamics of E5564, a lipid A antagonist, during an ascending single-dose clinical studyY Nancy Wong, Daniel Rossignol, Jeffrey R Rose, et al.
Innate Immunity|March 9, 2011
Deactivation of the lipopolysaccharide antagonist eritoran (E5564) by high-density lipoprotein-associated apolipoproteinsJacklyn G Fleischer, Dan Rossignol, Gordon A Francis, et al.
Chest|September 15, 2004
Experimental human endotoxemia is associated with depression of load-independent contractility indices: prevention by the lipid a analogue E5531Anand Kumar, Eugene Bunnell, Melvyn Lynn, et al.
Antimicrobial Agents and Chemotherapy|August 26, 2004
Safety, pharmacokinetics, pharmacodynamics, and plasma lipoprotein distribution of eritoran (E5564) during continuous intravenous infusion into healthy volunteersDaniel P Rossignol, Kishor M Wasan, Eugene Choo, et al.
Critical Care Medicine|August 8, 2009
Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsisMark Tidswell, William Tillis, Steven P Larosa, et al.
The Journal of Infectious Diseases|February 25, 2003
Blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemiaMelvyn Lynn, Daniel P Rossignol, Janice L Wheeler, et al.
Pageof 2